Jacqueline Palace
University of Oxford
455 Papers
1.5K Citations
Jacqueline Palace is an academic researcher from University of Oxford. The author has contributed to research in topics: Medicine & Neuromyelitis optica. The author has an hindex of 74, co-authored 391 publications. Previous affiliations of Jacqueline Palace include Guy's Hospital & Walton Centre.
Chat about Author
Papers
•Journal Article
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788)
Michael J. Levy,Michael J. Levy,Achim Berthele,Ho Jin Kim,Kazuo Fujihara,Kazuo Fujihara,Ichiro Nakashima,Ichiro Nakashima,Celia Oreja-Guevara,Jacqueline Palace,Sean J. Pittock,Murat Terzi,N. A. Totolyan,Shanthi Viswanathan,Kai-Chen Wang,A Pace,Marcus Yountz,Diane Lawson,Eva-Laudon Meyer,Dean M. Wingerchuk +19 more
TL;DR: In patients in PREVENT who had previously received rituximab, the risk of adjudicated relapse was significantly lower with eculizumab than with placebo, and rates of serious infections were similarly low with eulogismab and placebo.
3
•Journal Article
New Acute Severity Scale for Neuromyelitis Optica Relapses (P5.249)
Michael J. Levy,Maureen A. Mealy,Sven Jarius,Friedemann Paul,Orhan Aktas,Simon Broadley,Philippe Cabre,May H. Han,Anu Jacob,Gareth R. John,Maria Isabel Leite,Romain Marignier,Ichiro Nakashima,Jacqueline Palace,Sven Schippling,Anthony Traboulsee,Brian G. Weinshenker,Dean M. Wingerchuk +17 more
TL;DR: The NMO Severity Scale (NMOSS) is a new NMO-specific disability scale for future clinical trials based on the EDSS but was modified to increase the sensitivity to visual acuity and visual fields.
3
•Journal Article
Pharmacokinetic/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the phase 3 PREVENT study
Achim Berthele,Celia Oreja-Guevara,Jacqueline Palace,Dean M. Wingerchuk,Sean J. Pittock,Michael J. Levy,Ichiro Nakashima,Pratap Singh,X Gao,R Pelto,Kazuo Fujihara +10 more
3